[PEGASUS or COMPASS? A guide for a wise clinical choice]

Recenti Prog Med. 2019 Nov;110(11):518-520. doi: 10.1701/3265.32325.
[Article in Italian]

Abstract

The recent publication of the PEGASUS and COMPASS studies could have a great influence on the clinical management of patients with stable ischemic heart disease. In the presence of possible eligibility for both approaches, a practical tool based on inclusion/exclusion criteria of the two studies could be useful for clinical decision of ideal treatment for suitable patients. We therefore report a simple nomogram helpful in identifying the treatment indicated on the base of patient's characteristics.

Publication types

  • Editorial

MeSH terms

  • Aspirin / administration & dosage*
  • Cerebrovascular Disorders / drug therapy
  • Clinical Decision-Making
  • Clinical Protocols*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Factor Xa Inhibitors / administration & dosage*
  • Humans
  • Myocardial Infarction / drug therapy
  • Myocardial Ischemia / drug therapy*
  • Peripheral Vascular Diseases / drug therapy
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Randomized Controlled Trials as Topic
  • Registries
  • Risk
  • Rivaroxaban / administration & dosage*
  • Ticagrelor / administration & dosage*

Substances

  • Factor Xa Inhibitors
  • Platelet Aggregation Inhibitors
  • Rivaroxaban
  • Ticagrelor
  • Aspirin